Nanomedicines
Design, Delivery and Detection
Herausgeber: Braddock, Martin
Nanomedicines
Design, Delivery and Detection
Herausgeber: Braddock, Martin
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book will provide an overview of the chemistry of nanocarrier design and the considerations that need to be made when developing a nanomedicine.
Andere Kunden interessierten sich auch für
- Structural Genomics, Part a105,99 €
- Nanotechnology for Drug Delivery and Pharmaceuticals113,99 €
- Keith Mitchelson (ed.)New High Throughput Technologies for DNA Sequencing and Genomics162,99 €
- Senescence, Senotherapeutics and Mitochondria140,99 €
- Jonathan SimonNanomedicine245,99 €
- Jonathan SimonNanomedicine119,99 €
- Amal Ali Elkordy (Faculty of Health Sci Professor of PharmaceuticsFormulation of Monoclonal Antibody Therapies143,99 €
-
-
-
This book will provide an overview of the chemistry of nanocarrier design and the considerations that need to be made when developing a nanomedicine.
Produktdetails
- Produktdetails
- Drug Discovery
- Verlag: Royal Society of Chemistry
- Seitenzahl: 370
- Erscheinungstermin: 28. April 2016
- Englisch
- Abmessung: 234mm x 163mm x 25mm
- Gewicht: 714g
- ISBN-13: 9781849739474
- ISBN-10: 1849739471
- Artikelnr.: 42810171
- Drug Discovery
- Verlag: Royal Society of Chemistry
- Seitenzahl: 370
- Erscheinungstermin: 28. April 2016
- Englisch
- Abmessung: 234mm x 163mm x 25mm
- Gewicht: 714g
- ISBN-13: 9781849739474
- ISBN-10: 1849739471
- Artikelnr.: 42810171
Design Considerations for Properties of Nanocarriers on the Disposition and
Efficiency of Drug and Gene Delivery; Targeting Cyclins and
Cyclin-Dependent Kinases Involved in Cell Cycle Regulation by RNAi as a
Potential Cancer Therapy; Nanoparticle carriers to overcome biological
barriers to siRNA delivery; Magnetic targeting as a vehicle for delivery of
nanomedicines; Development of Theranostics - Imaging Considerations and
Targeted Drug Delivery; The Role of Imaging in Nanomedicine Development and
Clinical Translation; Anticancer agent-incorporating polymeric micelles:
from bench to bedside; Polymeric Nanoparticles and Cancer: Lessons Learnt
from CRLX101; Nanodelivery Strategies in Breast Cancer Chemotherapy;
Developing a Predictable Regulatory Path for Nanomedicines by Accurate and
Objective Particle Measurement; Nanomedicine: Promises and Challenges; The
Challenge of Regulating Nanomedicine: Key Issues; Doxil® - The First
FDA-Approved Nano-Drug: From Basics via CMC, Cell Culture and Animal
Studies to Clinical Use
Efficiency of Drug and Gene Delivery; Targeting Cyclins and
Cyclin-Dependent Kinases Involved in Cell Cycle Regulation by RNAi as a
Potential Cancer Therapy; Nanoparticle carriers to overcome biological
barriers to siRNA delivery; Magnetic targeting as a vehicle for delivery of
nanomedicines; Development of Theranostics - Imaging Considerations and
Targeted Drug Delivery; The Role of Imaging in Nanomedicine Development and
Clinical Translation; Anticancer agent-incorporating polymeric micelles:
from bench to bedside; Polymeric Nanoparticles and Cancer: Lessons Learnt
from CRLX101; Nanodelivery Strategies in Breast Cancer Chemotherapy;
Developing a Predictable Regulatory Path for Nanomedicines by Accurate and
Objective Particle Measurement; Nanomedicine: Promises and Challenges; The
Challenge of Regulating Nanomedicine: Key Issues; Doxil® - The First
FDA-Approved Nano-Drug: From Basics via CMC, Cell Culture and Animal
Studies to Clinical Use
Design Considerations for Properties of Nanocarriers on the Disposition and
Efficiency of Drug and Gene Delivery; Targeting Cyclins and
Cyclin-Dependent Kinases Involved in Cell Cycle Regulation by RNAi as a
Potential Cancer Therapy; Nanoparticle carriers to overcome biological
barriers to siRNA delivery; Magnetic targeting as a vehicle for delivery of
nanomedicines; Development of Theranostics - Imaging Considerations and
Targeted Drug Delivery; The Role of Imaging in Nanomedicine Development and
Clinical Translation; Anticancer agent-incorporating polymeric micelles:
from bench to bedside; Polymeric Nanoparticles and Cancer: Lessons Learnt
from CRLX101; Nanodelivery Strategies in Breast Cancer Chemotherapy;
Developing a Predictable Regulatory Path for Nanomedicines by Accurate and
Objective Particle Measurement; Nanomedicine: Promises and Challenges; The
Challenge of Regulating Nanomedicine: Key Issues; Doxil® - The First
FDA-Approved Nano-Drug: From Basics via CMC, Cell Culture and Animal
Studies to Clinical Use
Efficiency of Drug and Gene Delivery; Targeting Cyclins and
Cyclin-Dependent Kinases Involved in Cell Cycle Regulation by RNAi as a
Potential Cancer Therapy; Nanoparticle carriers to overcome biological
barriers to siRNA delivery; Magnetic targeting as a vehicle for delivery of
nanomedicines; Development of Theranostics - Imaging Considerations and
Targeted Drug Delivery; The Role of Imaging in Nanomedicine Development and
Clinical Translation; Anticancer agent-incorporating polymeric micelles:
from bench to bedside; Polymeric Nanoparticles and Cancer: Lessons Learnt
from CRLX101; Nanodelivery Strategies in Breast Cancer Chemotherapy;
Developing a Predictable Regulatory Path for Nanomedicines by Accurate and
Objective Particle Measurement; Nanomedicine: Promises and Challenges; The
Challenge of Regulating Nanomedicine: Key Issues; Doxil® - The First
FDA-Approved Nano-Drug: From Basics via CMC, Cell Culture and Animal
Studies to Clinical Use